Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21694542 | 0.94 | CA2 (0.42) | ZDHHC7CA2CPB2CA1 | |
| SCHEMBL1769475 | 0.91 | CA2 (0.42) | ZDHHC7CA2GPR84FFAR1MAPT | |
| SCHEMBL7070785 | 0.88 | ZDHHC7 (0.50) | ZDHHC7CA2GPR84FFAR1MAPT | |
| SCHEMBL19690704 | 0.88 | ZDHHC7 (0.50) | ZDHHC7CA2GPR84FFAR1MAPT | |
| SCHEMBL13269368 | 0.86 | ZDHHC7 (0.47) | ZDHHC7CA2GPR84FFAR1MAPT | |
| SCHEMBL21694632 | 0.86 | CA2 (0.37) | ZDHHC7CA2MAPTCPB2CA1 | |
| SCHEMBL8193028 | 0.85 | ZDHHC7 (0.58) | ZDHHC7CA2GPR84FFAR1MAPT | |
| SCHEMBL5355140 | 0.85 | NAAA (0.50) | ZDHHC7MAPTFAAH | |
| SCHEMBL234311 | 0.84 | CA2 (0.47) | ZDHHC7CA2CPB2CA1 | |
| SCHEMBL5312017 | 0.84 | ZDHHC7 (0.43) | ZDHHC7CA2GPR84FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120093896-A1 | USE OF NANODISPERSIONS TO PROTECT WATER-SOLUBLE INGREDIENTS IN COSMETIC END FORMULATIONS | CIBA CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093896-A1 | USE OF NANODISPERSIONS TO PROTECT WATER-SOLUBLE INGREDIENTS IN COSMETIC END FORMULATIONS | CUTA, PROC, RBP1 | ZDHHC7 2339/4885CA2 2253/4885GPR84 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.